Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NRIX Nurix Therapeutics

未开盘 10-12 16:00:00 EDT

22.16

-0.19

-0.85%

盘后22.55

+0.39+1.76%

19:55 EDT

最高22.58	最低22.03	成交量285.24万
今开22.27	昨收22.35	日振幅2.46%
总市值22.91亿	流通市值16.42亿	总股本1.03亿
成交额6,333万	换手率3.85%	流通股本7,411万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":22.16,"timestamp":1791835200000,"preClose":22.35,"halted":0,"volume":2852398,"hourTrading":{"tag":"盘后","latestPrice":22.55,"preClose":22.16,"latestTime":"19:55 EDT","volume":1448354,"amount":32107170.1377,"timestamp":1791849348513,"change":0.39,"changeRate":0.017599,"amplitude":0.104824},"delay":0,"changeRate":-0.008501118568232718,"floatShares":74111900,"shares":103405813,"eps":-3.410201,"marketStatus":"未开盘","change":-0.19,"latestTime":"10-12 16:00:00 EDT","open":22.27,"high":22.575,"low":22.025,"amount":63332503.041102,"amplitude":0.024609,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.410201,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791878400000},"marketStatusCode":0,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":22.35,"preHourTrading":{"tag":"盘前","latestPrice":22,"preClose":22.35,"latestTime":"09:27 EDT","volume":2080,"amount":46543.109599999996,"timestamp":1791811660026,"change":-0.35,"changeRate":-0.01566,"amplitude":0.026846},"postHourTrading":{"tag":"盘后","latestPrice":22.55,"preClose":22.16,"latestTime":"19:55 EDT","volume":1448354,"amount":32107170.1377,"timestamp":1791849348513,"change":0.39,"changeRate":0.017599,"amplitude":0.104824},"volumeRatio":1.861153,"impliedVol":1.504,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"1119072515","title":"Nurix宣布启动Stat6降解剂1期临床试验，获1000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1119072515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119072515?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:01","pubTimestamp":1785841286,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，因启动一项针对Stat6降解剂的1期临床试验，该公司已收到1000万美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181416540","title":"Nurix Therapeutics 宣布复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤临床试验Daybreak CLL-306首批患者入组，Bexobrutideg进入关键性3期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1181416540","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181416540?lang=zh_cn&edition=full","pubTime":"2026-08-04 13:01","pubTimestamp":1785819672,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics 宣布其关键性3期临床试验 Daybreak CLL-306 已完成首批患者入组。该试验旨在评估 bexobrutideg 针对复发/难治性慢性淋巴细胞白血病与小淋巴细胞淋巴瘤的疗效。这一里程碑事件，标志着这家生物科技公司向监管注册迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173713352","title":"Nurix Therapeutics 与罗氏携手推进Bexobrutinib在CLL、B细胞恶性肿瘤、MS及CSU领域的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1173713352","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173713352?lang=zh_cn&edition=full","pubTime":"2026-07-22 04:03","pubTimestamp":1784664195,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics 与罗氏达成合作，将共同推进药物Bexobrutinib在慢性淋巴细胞白血病（CLL）、B细胞恶性肿瘤、多发性硬化症（MS）以及慢性自发性荨麻疹（CSU）等多个适应症中的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144131445","title":"Nurix与罗氏研发成本分摊比例敲定：四六开，美国市场损益均分","url":"https://stock-news.laohu8.com/highlight/detail?id=1144131445","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144131445?lang=zh_cn&edition=full","pubTime":"2026-07-22 04:02","pubTimestamp":1784664136,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics与合作伙伴罗氏就一项关键研发协议达成成本分摊细则。根据协议，双方将共同承担候选药物的开发费用，其中Nurix Therapeutics负担40%，罗氏承担60%。此外，在美国市场产生的所有利润与亏损，将由两家公司平均分配。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136550694","title":"Nurix Therapeutics宣布与罗氏全球合作获得HSR批准，将共同开发并商业化潜在同类最佳BTK降解剂Bexobrutideg，覆盖恶性血液病、免疫学及神经学领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1136550694","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136550694?lang=zh_cn&edition=full","pubTime":"2026-07-22 04:02","pubTimestamp":1784664135,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，其与罗氏（Roche）达成的全球合作协议已获得美国《哈特-fullName-斯科特-罗迪诺反垄断改进法》（HSR）的批准。该合作旨在共同开发并商业化潜在同类最佳的布鲁顿酪氨酸激酶（BTK）降解剂Bexobrutideg，其应用范围将广泛覆盖恶性血液病、免疫学及神经学等多个治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120668408","title":"Nurix Therapeutics 1a期数据：重度预处理复发/难治性CLL/SLL患者中位无进展生存期达22.1个月，总缓解率83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120668408","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120668408?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:04","pubTimestamp":1781175859,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics公布的最新1a期临床试验数据显示，其研究性疗法在重度预处理的复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者群体中，展现出令人鼓舞的疗效。该患者群体既往接受过多线治疗，临床需求高度未满足。关键疗效指标显示，患者的中位无进展生存期达到了22.1个月，总缓解率高达83%。这些积极数据为后续临床开发提供了有力支持，并凸显了该疗法在治疗这一难治性血液恶性肿瘤方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115642144","title":"Nurix Therapeutics将公布Btk降解剂Bexobrutideg最新1a/b期数据，凸显在复发/难治性CLL/SLL中的持久应答及早期治疗线中的积极活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1115642144","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115642144?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:01","pubTimestamp":1781175683,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics即将公布其Btk降解剂Bexobrutideg的更新版1a/b期临床试验结果。最新数据显示，该药物在治疗复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中，能够诱导出持久的治疗应答。同时，在更早治疗线中的应用也展现出令人鼓舞的活性，为拓展其临床适用范围带来了希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163288696","title":"Nurix Therapeutics公布二线BTKi经治、BCL2i初治CLL患者92.9%客观缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1163288696","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163288696?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:01","pubTimestamp":1781175679,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics公布了其药物在二线治疗慢性淋巴细胞白血病患者中的最新数据。这些患者先前接受过布鲁顿酪氨酸激酶抑制剂治疗，但未接触过BCL2抑制剂。结果显示，客观缓解率达到了92.9%，展现了显著的临床活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100114","title":"罗氏(RHHBY)收购Nurix(NRIX)旗下靶向降解剂Bexobrutideg的商业开发权益 涉资最高可达30亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100114","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641100114?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:11","pubTimestamp":1780909874,"startTime":"0","endTime":"0","summary":"当地时间周一，临床阶段生物制药公司Nurix Therapeutics正式宣布，已与全球跨国制药巨头罗氏达成一项总额最高可达30亿美元的全球战略合作协议。两家公司将共同开发并商业化口服BTK降解剂Bexobrutideg。据介绍，本次让罗氏不惜砸下重金的核心资产Bexobrutideg，是一款具备“同类最佳”潜力的口服、可穿透血脑屏障的小分子BTK靶向蛋白降解剂。截至本文发稿，Nurix美股盘前大涨56.15%，最新报22.90美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301245","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4139","NRIX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160719437","title":"罗氏将向Nurix支付高达23亿美元的癌症药物交易款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1160719437","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160719437?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:42","pubTimestamp":1780908153,"startTime":"0","endTime":"0","summary":"6月5日，Nurix Therapeutics盘前一度飙涨近70%！罗氏发表声明称，已与生物制药公司Nurix Therapeutics达成独家许可与合作协议。罗氏将支付最高23亿美元，以获得Nurix一种实验性血液癌症药物的权益。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108856417","title":"罗氏与Nurix Therapeutics就BTK降解剂Bexobrutideg达成全球合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1108856417","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108856417?lang=zh_cn&edition=full","pubTime":"2026-06-08 13:20","pubTimestamp":1780896038,"startTime":"0","endTime":"0","summary":"罗氏控股公司宣布，将与Nurix Therapeutics建立全球性合作，共同开发和商业化一款潜在同类最佳的BTK降解剂Bexobrutideg，其应用范围将覆盖恶性血液肿瘤、免疫学及神经学领域。\n根据协议条款，Nurix公司将获得高达23亿美元的总交易价值，其中包括7亿美元的预付款。双方将共同承担开发成本，其中Nurix分担40%，罗氏承担60%。在美国市场的商业化方面，利润与亏损将由两家公司均摊。\n此项合作预计将于2026年第三季度完成，具体取决于相关条件的满足。针对复发或难治性慢性淋巴细胞白血病，Bexobrutideg的三期临床试验计划于2026年夏季启动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155111507","title":"Nurix Therapeutics宣布Bexobrutideg将在2026年欧洲血液学协会大会进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1155111507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155111507?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:06","pubTimestamp":1778616379,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，其候选药物Bexobrutideg将在2026年欧洲血液学协会（EHA）大会上进行口头报告。这一进展标志着该药物在血液学领域的研究获得了重要认可，并将向全球血液学专家展示其最新的临床数据与研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658359","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658359?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:35","pubTimestamp":1741016156,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时35分，Nurix Therapeutics, Inc.股票出现异动，股价急速跳水5.18%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514331683","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331683","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514331683?lang=zh_cn&edition=full","pubTime":"2025-02-28 01:39","pubTimestamp":1740677995,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日01时39分，Nurix Therapeutics, Inc.股票出现异动，股价大幅下跌5.10%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514726011","title":"Nurix Therapeutics, Inc.盘中异动 临近午盘股价大跌5.04%报16.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514726011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514726011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:38","pubTimestamp":1740501495,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时38分，Nurix Therapeutics, Inc.股票出现异动，股价大幅跳水5.04%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510353845","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.00%报17.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510353845?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:07","pubTimestamp":1739297270,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日02时07分，Nurix Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509231285","title":"Nurix Therapeutics, Inc.盘中异动 大幅上涨5.00%报19.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509231285?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:24","pubTimestamp":1738776295,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时24分，Nurix Therapeutics, Inc.股票出现异动，股价急速拉升5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508178878","title":"Nurix Therapeutics, Inc.盘中异动 临近收盘急速跳水5.07%报18.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178878","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508178878?lang=zh_cn&edition=full","pubTime":"2025-02-04 04:44","pubTimestamp":1738615480,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日04时44分，Nurix Therapeutics, Inc.股票出现波动，股价大幅跳水5.07%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507692295","title":"Nurix Therapeutics, Inc.2024财年实现净利润-1.94亿美元，同比减少34.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507692295","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507692295?lang=zh_cn&edition=full","pubTime":"2025-01-30 12:01","pubTimestamp":1738209666,"startTime":"0","endTime":"0","summary":"1月30日，Nurix Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.94亿美元，同比减少34.72%；其中营业收入为54.55百万美元，同比减少29.15%，每股基本收益为-2.88美元。机构评级：截至2025年1月30日，当前有17家机构对Nurix Therapeutics, Inc.目标价做出预测，其中目标均价为33.18美元，其中最低目标价为26.00美元，最高目标价为41.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507659941","title":"加拿大皇家银行：维持Nurix Therapeutics(NRIX.US)评级，由优于大市调整至优于大市评级, 目标价由26.00美元调整至27.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507659941","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507659941?lang=zh_cn&edition=full","pubTime":"2025-01-30 01:36","pubTimestamp":1738172215,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Nurix Therapeutics(NRIX.US)评级，由优于大市调整至优于大市评级, 目标价由26.00美元调整至27.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30013647899048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0278},{"period":"1month","weight":-0.1489},{"period":"3month","weight":-0.0308},{"period":"6month","weight":0.3943},{"period":"1year","weight":1.058},{"period":"ytd","weight":0.1782}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nurix Therapeutics, Inc.于2009年8月27日在特拉华州注册成立，总部位于加利福尼亚州布里斯班。它是一家临床阶段的生物制药公司，专注于靶向蛋白质降解药物的发现、开发和商业化，旨在改善癌症和炎症性疾病患者的治疗选择。在人工智能（AI）集成发现引擎和E3连接酶生物学深厚专业知识的支持下，该公司推进了将蛋白质降解科学转化为临床疗法的差异化方法。Nurix的全资管道包括针对布鲁顿酪氨酸激酶（BTK）和Casitas B系淋巴瘤原癌基因B（CBL-B）的研究候选药物，以及临床前开发中的额外降解剂和降解剂抗体偶联物。Nurix与包括吉利德科学、赛诺菲和辉瑞在内的全球制药合作伙伴合作，还根据共同开发和共同商业化安排，为多个候选药物开展发现计划。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.5,"avgChangeRate":0.009892},{"month":6,"riseRate":0.666667,"avgChangeRate":0.159386},{"month":7,"riseRate":0.5,"avgChangeRate":0.064005},{"month":8,"riseRate":0.571429,"avgChangeRate":0.029558},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.003382},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.004847},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}